

# Carla J Greenbaum

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9313082/carla-j-greenbaum-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

115  
papers

9,389  
citations

48  
h-index

96  
g-index

121  
ext. papers

11,314  
ext. citations

10.6  
avg, IF

5.68  
L-index

#	Paper	IF	Citations
115	Characterising the age-dependent effects of risk factors on type 1 diabetes progression.. <i>Diabetologia</i> , <b>2022</b> , 65, 684	10.3	0
114	Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.. <i>Science Translational Medicine</i> , <b>2022</b> , 14, eabi4888	17.5	1
113	Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.. <i>Diabetes</i> , <b>2022</b> , 71, 610-623	0.9	3
112	Citrullination of glucokinase is linked to autoimmune diabetes.. <i>Nature Communications</i> , <b>2022</b> , 13, 1870	17.4	0
111	IL-6 receptor blockade does not slow $\beta$ cell loss in new-onset type 1 diabetes. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	4
110	Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	37
109	Uncovering Pathways to Personalized Therapies in Type 1 Diabetes. <i>Diabetes</i> , <b>2021</b> , 70, 831-841	0.9	8
108	A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care. <i>Diabetes</i> , <b>2021</b> , 70, 1029-1037	0.9	1
107	Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. <i>Endocrine Reviews</i> , <b>2021</b> , 42, 584-604	27.2	7
106	Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. <i>Nature Genetics</i> , <b>2021</b> , 53, 962-971	36.3	28
105	Pancreatic islet reserve in type 1 diabetes. <i>Annals of the New York Academy of Sciences</i> , <b>2021</b> , 1495, 40-54.	5.5	6
104	Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01. <i>Diabetes</i> , <b>2020</b> , 69, 1492-1502	0.9	17
103	C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet. <i>Diabetes Care</i> , <b>2020</b> , 43, 1836-1842	14.6	17
102	Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic $\beta$ cells. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	12
101	High residual C-peptide likely contributes to glycemic control in type 1 diabetes. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 1850-1862	15.9	36
100	Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	6
99	Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. <i>PLoS ONE</i> , <b>2020</b> , 15, e0242049	3.7	7

98	Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. <i>Diabetes Care</i> , <b>2020</b> , 43, 913-917	14.6	6
97	High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 178-186	14.6	19
96	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 5-12	14.6	111
95	Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. <i>Diabetes Care</i> , <b>2020</b> , 43, 418-425	14.6	15
94	Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. <i>Diabetes Care</i> 2020;43:913-917. <i>Diabetes Care</i> , <b>2020</b> , 43, e103-e104	14.6	1
93	Acute Hyperinsulinemia Alters Bone Turnover in Women and Men With Type 1 Diabetes. <i>JBMR Plus</i> , <b>2020</b> , 4, e10389	3.9	2
92	Abnormalities in proinsulin processing in islets from individuals with longstanding T1D. <i>Translational Research</i> , <b>2019</b> , 213, 90-99	11	18
91	Genetics Coming of Age in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2019</b> , 42, 189-191	14.6	10
90	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 603-613	59.2	269
89	Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes. <i>Diabetes</i> , <b>2019</b> , 68, 1819-1829	0.9	6
88	Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. <i>Diabetes Care</i> 2019;42:258-264. <i>Diabetes Care</i> , <b>2019</b> , 42, e85-e86	14.6	2
87	Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression. <i>Diabetes</i> , <b>2019</b> , 68, 1240-1250	0.9	14
86	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. <i>Diabetes</i> , <b>2019</b> , 68, 1267-1276	0.9	45
85	Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal Study. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2023	8.4	6
84	Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	21
83	B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	24
82	Disease-modifying Therapies for the Prevention of Type 1 Diabetes. <i>US Endocrinology</i> , <b>2019</b> , 15, 15	0.3	
81	Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. <i>Genes and Immunity</i> , <b>2019</b> , 20, 293-307	4.4	23

80	Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet <sup>®</sup> Pathway to Prevention. <i>Diabetes Care</i> , <b>2019</b> , 42, 2228-2236	14.6	10
79	Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. <i>Diabetologia</i> , <b>2019</b> , 62, 655-664	10.3	35
78	Analysis of pancreatic beta cell specific CD4 <sup>+</sup> T cells reveals a predominance of proinsulin specific cells. <i>Cellular Immunology</i> , <b>2019</b> , 335, 68-75	4.4	9
77	Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice. <i>Drugs</i> , <b>2019</b> , 79, 43-61	12.1	24
76	Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. <i>Diabetes Care</i> , <b>2019</b> , 42, 258-264	14.6	48
75	Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4 T Cells in Patients With Type 1 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 1356-1368	0.9	34
74	Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 653-661	14.6	30
73	ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. <i>Pediatric Diabetes</i> , <b>2018</b> , 19 Suppl 27, 20-27	3.6	44
72	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves $\beta$ Cell Function and Improves HbA <sub>1c</sub> in New-Onset Type 1 Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 1917-1925	14.6	56
71	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. <i>Diabetes Care</i> , <b>2018</b> , 41, 1887-1894	14.6	59
70	DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes. <i>Journal of Immunology</i> , <b>2018</b> , 201, 3524-3533	5.3	9
69	First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. <i>Diabetes Care</i> , <b>2018</b> , 41, 2396-2403	14.6	57
68	Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes. <i>Diabetologia</i> , <b>2018</b> , 61, 2356-2370	10.3	20
67	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. <i>Diabetes</i> , <b>2018</b> , 67, 1216-1225	0.9	24
66	Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to $\beta$ Cell Antigens Are Focused on a Unique Set of Epitopes. <i>Journal of Immunology</i> , <b>2017</b> , 199, 91-96	5.3	12
65	Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4 T Cells in Peripheral Blood of Subjects with Type 1 Diabetes. <i>Journal of Immunology</i> , <b>2017</b> , 199, 323-335	5.3	34
64	Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease. <i>Journal of Immunology</i> , <b>2017</b> , 199, 3011-3013	5.3	2
63	Assessment of $\beta$ Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 4428-4434	5.6	12

62	Understanding and preventing type 1 diabetes through the unique working model of TrialNet. <i>Diabetologia</i> , <b>2017</b> , 60, 2139-2147	10.3	39
61	Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 1891-1902	27.4	88
60	Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. <i>Clinical Immunology</i> , <b>2017</b> , 181, 67-74	9	5
59	Measurement of Pro-Islet Amyloid Polypeptide (1-48) in Diabetes and Islet Transplants. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2595-2603	5.6	24
58	Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. <i>Diabetes Care</i> , <b>2016</b> , 39, 1664-70	14.6	76
57	Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 356ra119	17.5	57
56	HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. <i>Diabetes</i> , <b>2016</b> , 65, 1109-19	0.9	37
55	Identification of tissue-specific cell death using methylation patterns of circulating DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E1826-34	11.5	35 <sup>o</sup>
54	The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. <i>Diabetologia</i> , <b>2016</b> , 59, 1186-95	10.3	29
53	Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2015</b> , 31, 588-94	7.5	19
52	The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. <i>Diabetes Care</i> , <b>2015</b> , 38, 940-2	14.6	8
51	Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. <i>Diabetes Care</i> , <b>2015</b> , 38, 1964-74	14.6	435
50	A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. <i>Diabetes Care</i> , <b>2015</b> , 38, 271-6	14.6	36
49	Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. <i>Diabetes Care</i> , <b>2015</b> , 38, 1975-85	14.6	52
48	Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?. <i>Pharmacological Research</i> , <b>2015</b> , 98, 3-8	10.2	12
47	Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 476-81	14.6	132
46	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 3285-96	15.9	157
45	Molecular signatures differentiate immune states in type 1 diabetic families. <i>Diabetes</i> , <b>2014</b> , 63, 3960-73	0.9	48

44	Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 14840-5	11.5	87
43	Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. <i>PLoS ONE</i> , <b>2014</b> , 9, e112882	3.7	28
42	Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. <i>Diabetes</i> , <b>2014</b> , 63, 3033-40	0.9	103
41	B-lymphocyte depletion with rituximab and Bcell function: two-year results. <i>Diabetes Care</i> , <b>2014</b> , 37, 453-9	14.6	144
40	Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. <i>Diabetes Care</i> , <b>2014</b> , 37, 1069-75	14.6	126
39	Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. <i>Diabetes</i> , <b>2013</b> , 62, 3766-74	0.9	222
38	Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2013</b> , 1, 284-94	18.1	124
37	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. <i>Lancet, The</i> , <b>2013</b> , 381, 1905-15	4.0	234
36	CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. <i>Immunology</i> , <b>2013</b> , 138, 269-79	7.8	31
35	Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e83811	3.7	72
34	Through the fog: recent clinical trials to preserve Bcell function in type 1 diabetes. <i>Diabetes</i> , <b>2012</b> , 61, 1323-30	0.9	33
33	Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. <i>Diabetes Care</i> , <b>2012</b> , 35, 1213-8	14.6	71
32	Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs Bcell function. <i>Diabetes</i> , <b>2012</b> , 61, 2340-8	0.9	234
31	Altered B cell homeostasis is associated with type 1 diabetes and carriers of the PTPN22 allelic variant. <i>Journal of Immunology</i> , <b>2012</b> , 188, 487-96	5.3	99
30	Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. <i>Diabetes</i> , <b>2012</b> , 61, 2066-73	0.9	216
29	Effect of rituximab on human in vivo antibody immune responses. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 1295-1302.e5	11.5	76
28	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2011</b> , 378, 412-9	4.0	403
27	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. <i>Lancet, The</i> , <b>2011</b> , 378, 319-27	4.0	263

26	Making progress: preserving beta cells in type 1 diabetes. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1243, 119-34	6.5	20
25	Metabolic tests to determine risk for type 1 diabetes in clinical trials. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2011</b> , 27, 584-9	7.5	10
24	Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new-onset type 1 diabetes. <i>Diabetes Care</i> , <b>2010</b> , 33, 826-32	14.6	114
23	Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. <i>Diabetes</i> , <b>2010</b> , 59, 407-15	0.9	208
22	Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). <i>Diabetes</i> , <b>2010</b> , 59, 2386-9	0.9	28
21	Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , <b>2009</b> , 32, 1603-7	14.6	45
20	Preservation of beta-cell function in autoantibody-positive youth with diabetes. <i>Diabetes Care</i> , <b>2009</b> , 32, 1839-44	14.6	66
19	Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. <i>Clinical Immunology</i> , <b>2009</b> , 132, 166-73	9	153
18	Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 2143-52	59.2	717
17	CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope. <i>Journal of Autoimmunity</i> , <b>2008</b> , 31, 30-41	15.5	46
16	The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. <i>Journal of Immunology</i> , <b>2008</b> , 181, 7350-5	5.3	233
15	A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. <i>Diabetes Care</i> , <b>2008</b> , 31, 528-33	14.6	88
14	Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. <i>Diabetes Care</i> , <b>2008</b> , 31, 1966-71	14.6	203
13	Type 1 Diabetes TrialNet--an international collaborative clinical trials network. <i>Annals of the New York Academy of Sciences</i> , <b>2008</b> , 1150, 14-24	6.5	81
12	Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. <i>Journal of Immunology</i> , <b>2007</b> , 179, 4704-10	5.3	271
11	Role of insulin resistance in predicting progression to type 1 diabetes. <i>Diabetes Care</i> , <b>2007</b> , 30, 2314-20	14.6	78
10	Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 1705-13	5.6	27
9	Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. <i>Diabetes Care</i> , <b>2006</b> , 29, 643-9	14.6	127

8	Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. <i>Journal of Immunology</i> , <b>2006</b> , 176, 2781-9	5.3	85
7	Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. <i>Journal of Autoimmunity</i> , <b>2005</b> , 25, 303-11	15.5	76
6	Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. <i>Diabetes Care</i> , <b>2005</b> , 28, 1068-76	14.6	492
5	GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. <i>Diabetes</i> , <b>2004</b> , 53, 1987-94	0.9	90
4	Insulin resistance in type 1 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2002</b> , 18, 192-200	7.5	107
3	Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. <i>Diabetes</i> , <b>2002</b> , 51, 951-7	0.9	84
2	Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. <i>Journal of Immunology</i> , <b>2001</b> , 166, 5265-70	5.3	77
1	Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1255-60	5.6	40